Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 2:58 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 745–768 of 1,913 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: PET Scanning Clear all
Recruiting Early Phase 1 Interventional

In-Human CXCR4 Imaging of Hematologic and Solid Tumors Using [68Ga]-Pentixafor-PET

NCT05093335
View directory record Official record
Conditions
Non-Hodgkin Lymphoma, Multiple Myeloma, Histiocytic Neoplasms, Erdheim-Chester Disease, Rosai-Dorfman Disease
Interventions
[68Ga]-Pentixafor
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Oct 25, 2026, 2:58 AM EDT
Recruiting Phase 1Phase 2 Interventional

Pralatrexate With Bendamustine and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma

NCT07225985
View directory record Official record
Conditions
Recurrent T-Cell Non-Hodgkin Lymphoma, Refractory T-Cell Non-Hodgkin Lymphoma
Interventions
Bendamustine, Pralatrexate, Bone Marrow Aspiration, Bone Marrow Biopsy, Chest Radiography, Computed Tomography, Echocardiography Test, Lumbar Puncture, Magnetic Resonance Imaging, Multigated Acquisition Scan, Peripheral Blood Stem Cell Transplantation, Positron Emission Tomography, Questionnaire Administration, Total-Body Irradiation, Biospecimen Collection
Drug · Procedure · Other + 1 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Oct 25, 2026, 2:58 AM EDT
Recruiting Phase 2 Interventional

POSLUMA® (18F-rhPSMA-7.3) PET-CT for PIRADS 2/3 Lesions

NCT07220720
View directory record Official record
Conditions
Prostate
Interventions
Flotufolastat F 18
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 100 Years · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 25, 2026, 2:58 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Androgen Deprivation, With or Without pTVG-AR, and With or Without T-Cell Checkpoint Blockade, in Patients With Newly Diagnosed, High-Risk Prostate Cancer

NCT04989946
View directory record Official record
Conditions
Prostate Cancer
Interventions
Degarelix, pTVG-AR, Nivolumab, Cemiplimab, Fianlimab, FLT PET/CT
Drug · Biological
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older · Male only
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 25, 2026, 2:58 AM EDT
Completed Phase 2Phase 3 Interventional Results available

68Ga-PSMA PET/CT in Detecting Prostate Cancer Recurrence in Patients With Elevated PSA After Initial Treatment

NCT02673151
View directory record Official record
Conditions
Prostate Adenocarcinoma, PSA Failure, Recurrent Prostate Carcinoma
Interventions
Computed Tomography (CT) scan, 68Ga-PSMA-11, Positron Emission Tomography (PET)
Procedure · Drug
Lead sponsor
Andrei Iagaru
Other
Eligibility
18 Years and older · Male only
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Jan 13, 2022 · Synced Oct 25, 2026, 2:58 AM EDT
Enrolling by invitation Phase 4 Interventional

DaTSCAN Imaging in Aging and Neurodegenerative Disease

NCT01453127
View directory record Official record
Conditions
Dementia, Parkinsonism, Mild Cognitive Impairment, REM Sleep Behavior Disorder
Interventions
I-123 Ioflupane solution injection prior to SPECT scan (DaTscan), Single photon emission computed tomography (SPECT) scan
Drug · Device
Lead sponsor
Mayo Clinic
Other
Eligibility
40 Years to 90 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2026
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Oct 25, 2026, 2:58 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Testing Whether Cancers With Specific Mutations Respond Better to Glutaminase Inhibitor, Telaglenastat Hydrochloride, Anti-Cancer Treatment, BeGIN Study

NCT03872427
View directory record Official record
Conditions
Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, NF1 Mutation Positive Malignant Peripheral Nerve Sheath Tumor, Unresectable Malignant Solid Neoplasm
Interventions
Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Pharmacodynamic Study, Positron Emission Tomography, Telaglenastat Hydrochloride
Procedure · Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
31
States / cities
Birmingham, Alabama • Aventura, Florida • Coral Gables, Florida + 23 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Oct 25, 2026, 2:58 AM EDT
Terminated Not applicable Interventional Results available

Assessment of Coronary Artery Disease by Hybrid PET/CT

NCT00320931
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Hybrid PET/CT
Device
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 9, 2021 · Synced Oct 25, 2026, 2:58 AM EDT
Recruiting Early Phase 1 Interventional

Chemical-Shift-Encoded MRI for Active Bone Marrow Dosimetry in Radiopharmaceutical Therapy

NCT07609225
View directory record Official record
Conditions
Metastatic Castration-resistant Prostate Cancer
Interventions
3'-Deoxy-3'-[18F]-fluorothymidine, Chemical-shift-encoded MRI
Drug · Device
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older · Male only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Oct 25, 2026, 2:58 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional Results available

Trametinib and Navitoclax in Treating Patients With Advanced or Metastatic Solid Tumors

NCT02079740
View directory record Official record
Conditions
Metastatic Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Navitoclax, Positron Emission Tomography, Trametinib
Procedure · Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2027
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 25, 2026, 2:58 AM EDT
Completed Phase 2 Interventional Results available

Sirolimus to Treat Cowden Syndrome and Other PTEN Hamartomatous Tumor Syndromes

NCT00971789
View directory record Official record
Conditions
Cowden's Disease, Hamartoma Syndrome, Multiple
Interventions
fludeoxyglucose F 18, sirolimus, Clinical Videography
Radiation · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 30, 2015 · Synced Oct 25, 2026, 2:58 AM EDT
Active, not recruiting Phase 1 Interventional

Immune Response Activation for the Treatment of Unresectable Metastatic Colorectal Cancer or CEA Positive Metastatic Breast Cancer

NCT06130826
View directory record Official record
Conditions
Breast Carcinoma, Colorectal Carcinoma
Interventions
Biopsy, Biospecimen Collection, Bone Scan, Computed Tomography, Immunotherapy, Magnetic Resonance Imaging, Positron Emission Tomography, Stereotactic Body Radiation Therapy
Procedure · Drug · Radiation
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 25, 2026, 2:58 AM EDT
Completed Phase 1 Interventional

Siltuximab for the Prevention of CAR T Cell Related Cytokine Release Syndrome in Patients With CD19 Positive Non-Hodgkin Lymphoma

NCT05665725
View directory record Official record
Conditions
Non-Hodgkin Lymphoma
Interventions
Biospecimen Collection, Computed Tomography, Positron Emission Tomography, Siltuximab
Procedure · Biological
Lead sponsor
Timothy Voorhees
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 31, 2025 · Synced Oct 25, 2026, 2:58 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

A Molecular Anatomic Imaging Analysis of Tau in Progressive Supranuclear Palsy

NCT02605785
View directory record Official record
Conditions
Progressive Supranuclear Palsy
Interventions
F-18 AV 1451
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
35 Years and older
Enrollment
332 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2030
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 25, 2026, 2:58 AM EDT
Completed Phase 2 Interventional Results available

Neoadjuvant Platinum-based Chemotherapy for Patients With Resectable , Non-small Cell Lung Cancer With Switch to Chemotherapy Alternative in Nonresponders (NEOSCAN)

NCT01443078
View directory record Official record
Conditions
Lung Cancer
Interventions
pemetrexed, cisplatin, Carboplatin, Gemcitabine Hydrochloride, Vinorelbine Tartrate, Docetaxel
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
5
States / cities
Basking Ridge, New Jersey • Commack, New York • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2018 · Synced Oct 25, 2026, 2:58 AM EDT
Completed Not applicable Interventional

Standard and Delayed FDG PET/CT After Chemoradiation Therapy in Assessing Patients With Metastatic Head and Neck Squamous Cell Cancer

NCT03575949
View directory record Official record
Conditions
Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Malignant Neoplasm in the Spine
Interventions
Computed Tomography, Fludeoxyglucose F-18, Positron Emission Tomography
Procedure · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 14, 2024 · Synced Oct 25, 2026, 2:58 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

CB1R in Synthetic Psychoactive Cannabinoids

NCT03539575
View directory record Official record
Conditions
Drug Dependence
Interventions
[11-C]OMAR
Other
Lead sponsor
Yale University
Other
Eligibility
18 Years to 55 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2026
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Oct 25, 2026, 2:58 AM EDT
Completed Phase 2 Interventional Results available

FDG and FMISO PET Hypoxia Evaluation in Cervical Cancer

NCT00559377
View directory record Official record
Conditions
Cervical Adenocarcinoma, Cervical Squamous Cell Carcinoma, Stage IB Cervical Cancer, Stage IIA Cervical Cancer, Stage IIB Cervical Cancer, Stage III Cervical Cancer, Stage IVA Cervical Cancer, Stage IVB Cervical Cancer
Interventions
18F-fluoromisonidazole, fluorodeoxyglucose F 18, positron emission tomography, tissue oxygen measurement
Other · Radiation · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 30, 2016 · Synced Oct 25, 2026, 2:58 AM EDT
Active, not recruiting Not applicable Interventional

Diffusion MRI for Head and Neck Cancer

NCT04251481
View directory record Official record
Conditions
Head Cancer Neck
Interventions
PET/MRI with FDG, MRI scan without contrast, MRI with gadolinium
Radiation
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Oct 25, 2026, 2:58 AM EDT
Completed Phase 2Phase 3 Interventional Results available

68Ga PSMA PET for Patients With Biochemical Recurrence of Prostate Cancer

NCT03389451
View directory record Official record
Conditions
Prostate Cancer, Prostatic Neoplasm, Prostatic Neoplasms, Castration-Resistant, Prostatic Cancer Recurrent, Prostatic Cancer Metastatic
Interventions
Ga-68 PSMA-HBED-CC PET
Drug
Lead sponsor
Michael Graham PhD, MD
Other
Eligibility
18 Years and older · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Jul 12, 2024 · Synced Oct 25, 2026, 2:58 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Dopaminergic Effects of Adjunctive Aripiprazole on the Brain in Treatment-Resistant Depression

NCT00953745
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Escitalopram, Aripiprazole, Placebo Capsule, Placebo Tablet
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 55 Years
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 19, 2018 · Synced Oct 25, 2026, 2:58 AM EDT
Recruiting No phase listed Observational

Flotufolastat F 18 PET in Men With Very Low PSA Recurrence

NCT06862856
View directory record Official record
Conditions
Prostate Cancer (Adenocarcinoma), Prostate Specific Antigen
Interventions
Positron Emission Tomography (PET)
Diagnostic Test
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older · Male only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 15, 2026 · Synced Oct 25, 2026, 2:58 AM EDT
Recruiting Phase 1 Interventional

18F-AraG PET/CT as a Non-Invasive Imaging Biomarker for Chemoradiation Treatment Response in Esophageal Cancer

NCT06414902
View directory record Official record
Conditions
Esophageal Cancer
Interventions
ArabinoFuranosylGuanine [18F]F-AraG
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Oct 25, 2026, 2:58 AM EDT
Recruiting Phase 3 Interventional

Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial

NCT06500481
View directory record Official record
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Neoplasm in the Leptomeninges, Stage IV Lung Cancer AJCC v8
Interventions
Biospecimen Collection, Computed Tomography, Involved-Field Radiation Therapy, Lumbar Puncture, Magnetic Resonance Imaging, Positron Emission Tomography, Proton Beam Craniospinal Irradiation, Quality-of-Life Assessment
Procedure · Radiation · Other
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2033
U.S. locations
58
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Encinitas, California + 45 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 25, 2026, 2:58 AM EDT